middle.news
How Will InhaleRx’s $38.5M Funding Fuel Its Expanded Clinical Trials?
10:44pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Will InhaleRx’s $38.5M Funding Fuel Its Expanded Clinical Trials?
10:44pm on Friday 29th of August, 2025 AEST
Key Points
Half-year loss increased to $854,332
Secured $38.5 million funding facility from Clendon Biotech Capital
Expanded Phase 2 trial for IRX211 Breakthrough Cancer Pain treatment
Phase 1 trial preparations underway for IRX616a Panic Disorder treatment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inhalerx (ASX:IRX)
OPEN ARTICLE